Singapore-headquartered healthtech firm Docquity has launched Engage, an AI and insights-powered platform designed to transform how pharmaceutical companies interact with healthcare professionals across Asia. Drawing from its network of over 500,000 verified doctors, the tool delivers real-time visibility into clinician behaviours, preferences and engagement patterns to guide more targeted campaigns. Already live in production with a multinational partner in the Philippines, Engage marks Docquity’s push into advanced analytics amid rising demand for compliant, data-driven pharma strategies.
Traditional pharma outreach relies on blunt metrics like visit frequency or content views, often missing the nuances of what drives HCP decisions. Engage changes that by blending anonymised real-world data with AI recommendations, helping field teams prioritise high-value interactions and measure impact beyond activity counts. For brand managers, it offers dashboards on audience segments, content resonance and campaign lift, all within regulatory guardrails for data privacy and promotion rules.
The platform rolled out first in Thailand and the Philippines, leveraging Docquity’s stronghold in Southeast Asia where digital adoption among doctors lags behind patient-side apps but accelerates post-pandemic. Partnerships with global pharma giants have validated the model, with early deployments showing improved engagement rates and faster feedback loops on drug launches or education drives. Expansion to Indonesia, Vietnam and Malaysia follows, tapping markets where HCP fragmentation challenges multinational rollouts.
Docquity’s founder sees Engage as the next evolution from its origins as a clinician collaboration app. By monetising aggregated insights ethically, the company bridges pharma’s need for precision marketing with doctors’ demand for relevant resources. Investors note the timing aligns with AI regulatory easing and budget pressures pushing life sciences towards ROI-focused tools.
Challenges include data silos across borders and varying HCP digital maturity, but Docquity’s verified network provides a defensible moat. Success stories from pilot clients highlight 20-30 per cent uplifts in key metrics, positioning Engage as a category leader in HCP intelligence. As Southeast Asia’s pharma market swells with generics and biosimilars, tools like this could level the playing field for local players against global incumbents. For ordinary doctors, Engage indirectly benefits through better-tailored education and peer insights, while pharma gains efficiency in a compliance-heavy landscape. Docquity’s bet on AI ethics and scale could redefine stakeholder ecosystems, turning fragmented markets into connected hubs.
